" />

Innovation Lab at Pacira Biosciences

September 28, 2019
7:30 AM - 12:30 PM

University of Colorado, Center for Surgical Innovations
BioScience 1 Building, 12635 E. Montview Blvd., Suite 170
Aurora, CO 80045
Venue website

Overview:
This course is designed for the obstetrics team including Obstetric & Gynecologic Surgeons, Maternal Fetal Specialists, Anesthesiologists, and Nursing leaders who are seeking to advance a platform enhancing patients’ experiences after surgery. This course includes lectures, hands-on workshops on fresh frozen human cadavers, and live model scanning. Techniques are taught by expert instructors, offering up to date evidence applicable to your surgical practice.

Objectives:

  • Describe the opioid epidemic as it specifically relates to the women’s health arena
  • Review legislative movement towards opioid minimization
  • Outline society guidelines addressing a multimodal approach for postsurgical care in obstetrics and gynecological procedures
  • Analyze the scientific literature that supports opioid avoidance
  • Build out an interactive multimodal and enhanced recovery pathway
  • Utilize a cadaveric model focused on surgical techniques applicable to addressing pain management in C-section as well as vaginal, open, and minimally invasive hysterectomy
  • Demonstrate skill in ultrasound guided transversus abdominis plane blocks, including live model scanning and cadaveric real time application

 

Saturday, September 28, 2019
7:30am – 12:30pm
Featuring: Sabry Ayad, Susan Crockett, Valentine Gibson
Jeffrey Gonzales, Steven McCarus, and William Salter

Location: University of Colorado, Center for Surgical Innovation
BioScience 1 Building, 12635 E. Montview Blvd, Suite 170, Aurora, CO 80045

Please register online here: www.EXPAREL.com/INNOVATIONLABS
Questions? Contact the Medical Innovation and Education team at either number: 210-897-9248 or 216-577-8668

Please see indication and Important Safety Information on the following page.

Indication
EXPAREL® (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL
Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products
Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions:
Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions:
Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis:
There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia:
Cases of methemoglobinemia have been reported with local anesthetic use.

Full Prescribing information is available at www.EXPAREL.com.

PP-EX-US-5112 07/19